Positive News SentimentPositive NewsNASDAQ:LNSR LENSAR (LNSR) Stock Price, News & Analysis $12.19 -0.40 (-3.18%) Closing price 08/27/2025 04:00 PM EasternExtended Trading$12.20 +0.01 (+0.08%) As of 08/27/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About LENSAR Stock (NASDAQ:LNSR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LENSAR alerts:Sign Up Key Stats Today's Range$12.19▼$12.6350-Day Range$12.19▼$13.3252-Week Range$3.80▼$17.31Volume60,595 shsAverage Volume57,760 shsMarket Capitalization$145.55 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingHold Company Overview LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida. Read More LENSAR Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreLNSR MarketRank™: LENSAR scored higher than 21% of companies evaluated by MarketBeat, and ranked 864th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingLENSAR has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageLENSAR has received no research coverage in the past 90 days.Read more about LENSAR's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of LENSAR is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENSAR is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about LENSAR's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.48% of the float of LENSAR has been sold short.Short Interest Ratio / Days to CoverLENSAR has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in LENSAR has recently increased by 2.36%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLENSAR does not currently pay a dividend.Dividend GrowthLENSAR does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.48% of the float of LENSAR has been sold short.Short Interest Ratio / Days to CoverLENSAR has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in LENSAR has recently increased by 2.36%, indicating that investor sentiment is decreasing. News and Social Media3.2 / 5News Sentiment1.80 News SentimentLENSAR has a news sentiment score of 1.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for LENSAR this week, compared to 1 article on an average week. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LENSAR insiders have not sold or bought any company stock.Percentage Held by Insiders38.52% of the stock of LENSAR is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.15% of the stock of LENSAR is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENSAR's insider trading history. Receive LNSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENSAR and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LNSR Stock News HeadlinesLensar (LNSR) Q2 Revenue Rises 10%August 15, 2025 | theglobeandmail.comLENSAR Reports Second Quarter 2025 Results and Provides Business UpdateAugust 7, 2025 | globenewswire.comNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the REAL fortune they expect to come from quantum computing - a $2 trillion explosion by 2035. The kicker? One company is America's FIRST commercial supplier of the material that makes it possible. | The Oxford Club (Ad)LENSAR, Inc. Grants 660 Restricted Stock Units to New Non-Executive Employees as Inducement for Employment - NasdaqJuly 3, 2025 | nasdaq.comLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SVT, LNSR, ICAD, SSBK on Behalf of ShareholdersJune 11, 2025 | morningstar.comM$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of SVT, SSBK, LNSR, iCAD to ActJune 10, 2025 | morningstar.comMSee More Headlines LNSR Stock Analysis - Frequently Asked Questions How have LNSR shares performed this year? LENSAR's stock was trading at $8.94 at the beginning of the year. Since then, LNSR shares have increased by 36.4% and is now trading at $12.19. How were LENSAR's earnings last quarter? LENSAR, Inc. (NASDAQ:LNSR) released its quarterly earnings results on Thursday, August, 7th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.08. The company earned $11.36 million during the quarter, compared to analyst estimates of $16.55 million. LENSAR had a negative trailing twelve-month return on equity of 737.30% and a negative net margin of 84.49%. Who are LENSAR's major shareholders? Top institutional investors of LENSAR include Brandes Investment Partners LP (4.72%), Groupe la Francaise (2.11%), Geode Capital Management LLC (1.86%) and Credit Industriel ET Commercial (1.43%). Insiders that own company stock include Thomas R Staab II and Gary M Winer. View institutional ownership trends. How do I buy shares of LENSAR? Shares of LNSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LENSAR own? Based on aggregate information from My MarketBeat watchlists, some other companies that LENSAR investors own include Arch Capital Group (ACGL), Aprea Therapeutics (APRE), Artelo Biosciences (ARTL), AstraZeneca (AZN), Baidu (BIDU), Cidara Therapeutics (CDTX) and Carlyle Group (CG). Company Calendar Last Earnings8/07/2025Today8/28/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:LNSR CIK1320350 Webwww.lensar.com Phone888-536-7271FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for LENSAR$15.00 High Price Target$15.00 Low Price Target$15.00 Potential Upside/Downside+23.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($4.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.40 million Net Margins-84.49% Pretax Margin-84.49% Return on Equity-737.30% Return on Assets-72.60% Debt Debt-to-Equity RatioN/A Current Ratio1.52 Quick Ratio0.88 Sales & Book Value Annual Sales$53.49 million Price / Sales2.72 Cash FlowN/A Price / Cash FlowN/A Book Value($1.93) per share Price / Book-6.32Miscellaneous Outstanding Shares11,940,000Free Float7,338,000Market Cap$145.55 million OptionableOptionable Beta0.50 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:LNSR) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENSAR With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.